CoChat

NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma

Jones, Martin R., Williamson, Laura M., Topham, James T., Lee, Michael K.C., Goytain, Angela, Ho, Julie, Denroche, Robert E., Jang, GunHo, Pleasance, Erin, Shen, Yaoquing, Karasinska, Joanna M., McGhie, John P., Gill, Sharlene, Lim, Howard J., Moore, Malcolm J., Wong, Hui-li, Ng, Tony, Yip, Stephen, Zhang, Wei, Sadeghi, Sara, Reisle, Carolyn, Mungall, Andrew J., Mungall, Karen L., Moore, Richard A., Ma, Yussanne, Knox, Jennifer J., Gallinger, Steven, Laskin, Janessa, Marra, Marco A., Schaeffer, David F., Jones, Steven J.M., Renouf, Daniel J. · 2019 · Clinical Cancer Research
Cited by 156

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Purpose: Gene fusions involving neuregulin 1 (NRG1) have been noted in multiple cancer types and have potential therapeutic implications. Although varying results have been reported in other cancer types, the efficacy of the HER-family kinase inhibitor afatinib in the treatment of NRG1 fusion–positive pancreatic ductal adenocarcinoma is not fully understood. Experimental Design: Forty-seven patients with pancreatic ductal adenocarcinoma received comprehensive whole-genome and transcriptome sequencing and analysis. Two patients with gene fusions involving NRG1 received afatinib treatment, with response measured by pretreatment and posttreatment PET/CT imaging. Results: Three of 47 (6%) patients with advanced pancreatic ductal adenocarcinoma were identified as KRAS wild type by whole-genome sequencing. All KRAS wild-type tumors were positive for gene fusions involving the ERBB3 ligand NRG1. Two of 3 patients with NRG1 fusion–positive tumors were treated with afatinib and demonstrated a significant and rapid response while on therapy. Conclusions: This work adds to a growing body of evidence that NRG1 gene fusions are recurrent, therapeutically actionable genomic events in pancreatic cancers. Based on the clinical outcomes described here, patients with KRAS wild-type tumors harboring NRG1 gene fusions may benefit from treatment with afatinib. See related commentary by Aguirre, p. 4589

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-19-0191

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 156

Metadata

Authors
Jones, M. R., Williamson, L. M., Topham, J. T., Lee, M. K. C., Goytain, A., Ho, J., Denroche, R. E., Jang, G., Pleasance, E., Shen, Y., Karasinska, J. M., McGhie, J. P., Gill, S., Lim, H. J., Moore, M. J., Wong, H.-L., Ng, T., Yip, S., Zhang, W., Sadeghi, S., Reisle, C., Mungall, A. J., Mungall, K. L., Moore, R. A., Ma, Y., Knox, J. J., Gallinger, S., Laskin, J., Marra, M. A., Schaeffer, D. F., Jones, S. J. M., & Renouf, D. J.
Venue
Clinical Cancer Research
Published
2019-08-01
Volume
25
Issue
15
Pages
4674-4681
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2944179533
Cited by
156
References
9
FWCI
8.34
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-19-0191
The paper
Jones, M. R., Williamson, L. M., Topham, J. T., Lee, M. K. C., Goytain, A., Ho, J., Denroche, R. E., Jang, G., Pleasance, E., Shen, Y., Karasinska, J. M., McGhie, J. P., Gill, S., Lim, H. J., Moore, M. J., Wong, H.-L., Ng, T., Yip, S., Zhang, W., . . . Renouf, D. J. (2019). NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-19-0191

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.